Christina Arce

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 349 citations

Medicine, Oncology, Pharmacology +17

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

Michael A. Gibney, Christina Arce, Karen Byron et al. · Current Medical Research and Opinion · 2010 · 280 citations · Full text

Medicine, Endocrinology, Surgery +17

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Melanie Royce, Thomas Bachelot, Cristian Villanueva et al. · JAMA Oncology · 2018 · 68 citations · Full text

Medicine, Oncology, Pharmacology +15

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · Journal of Clinical Oncology · 2020 · 56 citations

Medicine, Oncology, Pharmacology +17

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2024 · 38 citations

Medicine, Oncology, Pharmacology +17